This prespecified analysis of the SELECT trial investigated the effects of semaglutide on weight loss and anthropometric indices in patients with established CVD and overweight or obesity without diabetes. Semaglutide resulted in sustained weight loss over 4 years, with a mean reduction of 10.2% at 208 weeks compared to 1.5% in the placebo group. Clinically meaningful weight loss was observed across various demographics. While semaglutide was associated with fewer serious adverse events, it also led to increased rates of trial product discontinuation, particularly in lower BMI categories.

Donna H. Ryan, Ildiko Lingvay, John Deanfield, Steven E. Kahn, Eric Barros, Bartolome Burguera, Helen M. Colhoun, Cintia Cercato, Dror Dicker, Deborah B. Horn, G. Kees Hovingh, Ole Kleist Jeppesen, Alexander Kokkinos, A. Michael Lincoff, Sebastian M. Meyhöfer, Tugce Kalayci Oral, Jorge Plutzky, André P. van Beek, John P. H. Wilding, Robert F. Kushner